Search

A study conducted by researchers at the First Affiliated Hospital of Xi'an Jiaotong University in China has found that pegylated interferon alpha-2b treatment can effectively achieve a high rate of functional cure in postpartum women with chronic hepatitis B virus (HBV) infection. The study included 150 HBeAg-negative postpartum women, with 47 receiving pegylated interferon alpha-2b treatment and 103 not receiving it. The results showed that the treatment group had higher rates of HBsAg loss and seroconversion compared to the non-treatment group. Factors such as baseline HBsAg levels, HBsAg at week 24, HBsAg decline at week 24, and postpartum flare were significantly associated with HBsAg loss. The study concluded that pegylated interferon alpha-2b treatment is a safe and effective option for postpartum women with chronic HBV infection, particularly for those with low baseline HBsAg levels and experiencing postpartum flare. [Extracted from the article]

A recent study conducted by researchers at the University of Gothenburg Sahlgrenska Academy explored the relationship between plasma interferon-alpha (IFNa) protein levels, adverse pregnancy outcomes, and the presence of autoantibodies in women with systemic lupus erythematosus (SLE). The study followed 76 women with SLE and found that higher levels of plasma IFNa protein were associated with small for gestational age (SGA) infants and lower birth weight. Preterm birth was associated with autoantibodies against chromatin. The researchers concluded that elevated IFNa protein levels may be a potential risk factor for lower birth weight in infants of women with SLE and further investigation is needed to understand the role of IFNa during SLE pregnancy. [Extracted from the article]

A recent study conducted by investigators at Capital Medical University in Beijing, China, explores the potential of combining cisplatin with a modified immunomodulatory agent, interferon-alpha genetically fused to a thermosensitive polypeptide, for the treatment of cervical cancer. The researchers found that this combination therapy demonstrated enhanced antitumor efficiency in mice with cervical cancer, compared to other treatment options. The fusion protein, IFN-ELP(V), showed a greatly enhanced circulation half-life in mice and efficiently inhibited the development of cervical cancer when combined with cisplatin. These findings suggest that the synergistic combination of thermosensitive polypeptide fused interferon-alpha and cisplatin could be a promising strategy for cervical cancer treatment. [Extracted from the article]

A recent report from the University of California Berkeley discusses the potential use of Synechocystis sp. PCC 6803, a unicellular photosynthetic microorganism, as a model for photo-biochemical research. The researchers explored the use of Synechocystis as a cell factory for the production of bioactive compounds, therapeutic proteins, and biofuels. They specifically focused on the over-expression and isolation of human interferon alpha-2 protein, which could have significant applications in the production of recombinant proteins. The study brings the concept of cyanobacterial cell factories closer to commercial viability. [Extracted from the article]

A recent report from the China-Japan Friendship Hospital in Beijing, China, discusses the case of a patient with chronic hepatitis B who developed interstitial lung disease (ILD) after receiving pegylated-interferon alpha (PEG-IFN alpha) treatment. The report highlights the need for further studies to understand the characteristics and outcomes of ILD induced by interferon therapy. The analysis of 45 cases revealed that ILD induced by interferon treatment can lead to decreased lung function and, in some cases, be fatal despite intensive treatment. The researchers recommend monitoring for ILD during interferon therapy and considering appropriate steroid treatment for patients with progressive manifestations. [Extracted from the article]

The patent application titled "Compositions And Methods Relating To The Treatment Of Diseases" by William Stimson discusses the use of interferon-alpha (IFN-alpha) in treating viral conditions such as respiratory, gastrointestinal, and neurological viral diseases. The inventor proposes a variant of interferon alpha 14, called HYBRID 2, as a potential treatment for viral infections. Experiments have shown the anti-viral effects of HYBRID 2 against various viruses, including SARS-CoV-1, SARS-CoV-2, HIV, RSV, and HSV1. The patent application suggests that HYBRID 2 could be administered through direct injection or sublingually, and low doses may be effective in reducing viral activity. The application also highlights the potential utility of HYBRID 2 in the treatment and prevention of viral infections, including a wide range of viruses. For more information, please refer to the full patent. [Extracted from the article]

A recent study conducted by the Infectious Diseases Department provides new insights into the treatment of chronic hepatitis B virus (HBV). The study focused on the use of pegylated interferon alpha 2a as a treatment for chronic hepatitis D, a co-infection with HBV. The research found that after 24 weeks of treatment, patients who achieved undetectable HDV RNA had long-term suppression of the virus. However, the study also noted that relapses were common, with more than 50% of patients experiencing a relapse. The research suggests that the virologic response at week 24 can help determine which patients will benefit from continuing treatment. [Extracted from the article]

A recent study conducted at the China-Japan Friendship Hospital in Beijing, China, explored the short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b (SI therapy) for advanced hepatic epithelioid hemangioendothelioma (EHE). The study included 29 patients with hepatic EHE who received SI therapy for a median duration of 8 months. The results showed that SI therapy was effective, with 41.4% of patients achieving a partial or complete response and 86.2% experiencing stable disease. Adverse events were observed in 18 patients, but no severe adverse events were recorded. The researchers concluded that SI therapy is a safe and effective treatment for hepatic EHE patients with good performance status. [Extracted from the article]

A recent report from the University of London discusses the use of interferon proteins to inhibit the replication of human cytomegalovirus (HCMV). The study found that pre-treatment of cells with interferon alpha (IFNa) led to robust and prolonged inhibition of HCMV replication, without obvious toxicity. The presence of the anti-viral factor SUMO-PML was associated with poor expression of HCMV immediate-early proteins. The research suggests that strain-specific combinations of anti-viral factors are involved in inhibiting HCMV replication in the presence of IFNa. This work supports the development of strategies involving IFNa to inhibit HCMV replication and highlights the complexity of the anti-viral response to HCMV. [Extracted from the article]

Researchers from Ruhr-University Bochum have conducted a retrospective case collection study on the use of pegylated interferon alpha-2a (PEG-IFNa) in the treatment of cutaneous T-cell lymphoma (CTCL). CTCL is a rare and largely incurable type of lymphoma with limited treatment options. The study found that PEG-IFNa, especially when combined with skin-directed therapies, was effective in treating CTCL. Approximately 36% of patients achieved complete remission, 36% achieved partial remission, and 29% had stable disease. Adverse events were reported in 18% of patients, leading to discontinuation of therapy in 2 patients. The most common concomitant therapies were oral PUVA phototherapy and local radiotherapy. This research provides valuable insights into the efficacy and adverse events associated with PEG-IFNa therapy for CTCL. [Extracted from the article]

For more information on this research see: The Efficacy and Safety of Pegylated Interferon α-2b-based Immunotherapy for Inactive Hepatitis B Surface Antigen Carriers. Keywords: Zhengzhou; People's Republic of China; Asia; Antigens; Antivirals; Biological Factors; Cytokines; Digestive System Diseases and Conditions; Drugs and Therapies; Gastroenterology; Health and Medicine; Hepatitis; Hepatitis B Antigens; Hepatitis B Surface Antigens; Immunology; Immunotherapy; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Peginterferon Alfa-2b Therapy; Peptides; Pharmaceuticals; Proteins; Surface Antigens EN Zhengzhou People's Republic of China Asia Antigens Antivirals Biological Factors Cytokines Digestive System Diseases and Conditions Drugs and Therapies Gastroenterology Health and Medicine Hepatitis Hepatitis B Antigens Hepatitis B Surface Antigens Immunology Immunotherapy Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Peginterferon Alfa-2b Therapy Peptides Pharmaceuticals Proteins Surface Antigens 1480 1480 1 11/06/23 20231110 NES 231110 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Investigators discuss new findings in Liver Diseases and Conditions - Hepatitis. [Extracted from the article]

According to the news reporters, the research concluded: "This case study provides in-depth, multifaceted exploration of norovirus treatment that can be used as a guidance for further research towards norovirus treatments." Keywords: Rotterdam; Netherlands; Europe; Antiinfectives; Antineoplastics; Antiretrovirals; Antivirals; Biological Factors; Caliciviridae; Common Variable Immunodeficiency; Cytokines; Drugs and Therapies; Foodborne Diseases and Conditions; Genetics; Health and Medicine; Immune System Diseases and Conditions; Immunoglobulins; Immunologic Deficiency Syndromes; Immunology; Immunoproteins; Influenza Therapy; Inhaled Antiinfectives; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Norovirus; Peptides; Pharmaceuticals; Proteins; Purine Nucleosides; RNA Viruses; Respiratory Agents; Respiratory Inhalant Products; Ribavirin Therapy; Risk and Prevention; Serum Globulins; Viral; Viral RNA; Virology EN Rotterdam Netherlands Europe Antiinfectives Antineoplastics Antiretrovirals Antivirals Biological Factors Caliciviridae Common Variable Immunodeficiency Cytokines Drugs and Therapies Foodborne Diseases and Conditions Genetics Health and Medicine Immune System Diseases and Conditions Immunoglobulins Immunologic Deficiency Syndromes Immunology Immunoproteins Influenza Therapy Inhaled Antiinfectives Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Norovirus Peptides Pharmaceuticals Proteins Purine Nucleosides RNA Viruses Respiratory Agents Respiratory Inhalant Products Ribavirin Therapy Risk and Prevention Serum Globulins Viral Viral RNA Virology 1491 1491 1 10/30/23 20231102 NES 231102 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Food Weekly News -- Researchers detail new data in Immune System Diseases and Conditions - Common Variable Immunodeficiency. [Extracted from the article]

Chromatin immunoprecipitation assays indicated that STAT1 protein could bind to the SPAG6 promoter, while the dual-luciferase reporter assay indicated that STAT1 could promote the expression of SPAG6." Chongqing, People's Republic of China, Asia, Biological Factors, Cytokines, Health and Medicine, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Neoplasms, Peptides, Proteins Keywords: Chongqing; People's Republic of China; Asia; Biological Factors; Cytokines; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Neoplasms; Peptides; Proteins EN Chongqing People's Republic of China Asia Biological Factors Cytokines Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Neoplasms Peptides Proteins 1355 1355 1 10/30/23 20231031 NES 231031 2023 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Neoplasms. [Extracted from the article]

Keywords: Selangor; Malaysia; Asia; Biological Factors; Cytokines; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Neurodegenerative Diseases and Conditions; Peptides; Proteins EN Selangor Malaysia Asia Biological Factors Cytokines Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Neurodegenerative Diseases and Conditions Peptides Proteins 432 432 1 09/19/23 20230923 NES 230923 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on Neurodegenerative Diseases and Conditions is the subject of a report. Selangor, Malaysia, Asia, Biological Factors, Cytokines, Intercellular Signaling Peptides and Proteins, Interferon-alpha, Interferons, Neurodegenerative Diseases and Conditions, Peptides, Proteins, Interferon Type I. [Extracted from the article]

Keywords: Krakow; Poland; Europe; Angiogenic Proteins; Biological Factors; CXC Chemokines; Cancer; Connective Tissue Cells; Cytokines; Endothelial Growth Factors; Fibroblasts; Growth Factor Receptors; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukin-8; Interleukins; Membrane Proteins; Oncology; Peptides; Phosphotransferases; Protein Kinases; Proteins; Receptor Protein-Tyrosine Kinases; Risk and Prevention; Systemic Scleroderma; Systemic Sclerosis; VEGF; Vascular Endothelial Growth Factors EN Krakow Poland Europe Angiogenic Proteins Biological Factors CXC Chemokines Cancer Connective Tissue Cells Cytokines Endothelial Growth Factors Fibroblasts Growth Factor Receptors Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukin-8 Interleukins Membrane Proteins Oncology Peptides Phosphotransferases Protein Kinases Proteins Receptor Protein-Tyrosine Kinases Risk and Prevention Systemic Scleroderma Systemic Sclerosis VEGF Vascular Endothelial Growth Factors 711 711 1 09/11/23 20230912 NES 230912 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Systemic Sclerosis have been published. For more information on this research see: Association Between Clinical Features and Course of Systemic Sclerosis and Serum Interleukin-8, Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Interferon Alpha. [Extracted from the article]

The role of B cell IFN alpha signaling, T cells, and Myd88 signaling was determined using B cell-specific IFN alpha receptor-knockout, CD4+ T cell-depleted, or Myd88-knockout mice, respectively. Keywords: Toronto; Canada; North and Central America; Antibodies; Autoantibodies; Autoimmune Diseases and Conditions; Bioengineering; Biological Factors; Biotechnology; Blood Proteins; Cybersecurity; Cytokines; Drugs and Therapies; Gene Therapy; Health and Medicine; Immunology; Immunoproteins; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Lupus; Peptides; Proteins; Systemic Lupus Erythematosus EN Toronto Canada North and Central America Antibodies Autoantibodies Autoimmune Diseases and Conditions Bioengineering Biological Factors Biotechnology Blood Proteins Cybersecurity Cytokines Drugs and Therapies Gene Therapy Health and Medicine Immunology Immunoproteins Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Lupus Peptides Proteins Systemic Lupus Erythematosus 1087 1087 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Current study results on Biotechnology - Gene Therapy have been published. [Extracted from the article]

Keywords: Zhejiang; People's Republic of China; Asia; Biological Factors; Cytokines; DNA Virus Infections; DNA Viruses; Genetics; Gram-Positive Asporogenous Rods; Gram-Positive Bacteria; Gram-Positive Rods; Health and Medicine; Human Papillomavirus; Inflammation; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Lactobacillaceae; Lactobacillales; Lactobacillus; Papillomavirus Infections; Peptides; Proteins; Tumor Virus Infections; Viral; Virology EN Zhejiang People's Republic of China Asia Biological Factors Cytokines DNA Virus Infections DNA Viruses Genetics Gram-Positive Asporogenous Rods Gram-Positive Bacteria Gram-Positive Rods Health and Medicine Human Papillomavirus Inflammation Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Lactobacillaceae Lactobacillales Lactobacillus Papillomavirus Infections Peptides Proteins Tumor Virus Infections Viral Virology 437 437 1 08/21/23 20230825 NES 230825 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Data detailed on Tumor Virus Infections - Papillomavirus Infections have been presented. Zhejiang, People's Republic of China, Asia, Biological Factors, Cytokines, DNA Virus Infections, DNA Viruses, Genetics, Gram-Positive Asporogenous Rods, Gram-Positive Bacteria, Gram-Positive Rods, Health and Medicine, Human Papillomavirus, Inflammation, Intercellular Signaling Peptides and Proteins, Interferon-alpha, Interferons, Lactobacillaceae, Lactobacillales, Interferon Type I, Lactobacillus, Papillomavirus Infections, Peptides, Proteins, Tumor Virus Infections, Viral, Virology. [Extracted from the article]

History of chronic liver disease from any cause other than chronic HBV infection. Keywords: Antigens; Biological Factors; Bioscience; Chemicals; Chronic Hepatitis; Chronic Hepatitis B Virus; Clinical Research; Clinical Trials and Studies; Combination Therapy; Cytokines; DNA Viruses; Digestive System Diseases and Conditions; Drugs and Therapies; Gastroenterology; Health and Medicine; Hepadnaviridae; Hepatitis; Hepatitis B Virus; Hepatology; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Liver Diseases and Conditions - Chronic Hepatitis B Virus; Orthohepadnavirus; Peptides; Pharmaceuticals; Proteins; Risk and Prevention; Subcutaneous Injections; Virology EN Antigens Biological Factors Bioscience Chemicals Chronic Hepatitis Chronic Hepatitis B Virus Clinical Research Clinical Trials and Studies Combination Therapy Cytokines DNA Viruses Digestive System Diseases and Conditions Drugs and Therapies Gastroenterology Health and Medicine Hepadnaviridae Hepatitis Hepatitis B Virus Hepatology Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Liver Diseases and Conditions - Chronic Hepatitis B Virus Orthohepadnavirus Peptides Pharmaceuticals Proteins Risk and Prevention Subcutaneous Injections Virology 219 219 1 08/14/23 20230818 NES 230818 2023 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Staff editors report on the newly launched clinical trial, NCT05970289, which has the following summary description: "This study will evaluate the efficacy and safety of PEG-IFNa alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.". [Extracted from the article]

Keywords for this news article include: National Medical Center of Occidente, Antibiotics, Antineoplastics, Pharmaceuticals, Cytokines, Neoplasia, Pharmacology, Indolequinones, Interferon-alpha, Interferon Type I, Mitomycin Therapy, Biological Factors, Drugs and Therapies, Health and Medicine, Intercellular Signaling Peptides and Proteins. Keywords: Antibiotics; Antineoplastics; Biological Factors; Cytokines; Drugs and Therapies; Health and Medicine; Indolequinones; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Mitomycin Therapy; Mitomycins; Neoplasia; Peptides; Pharmaceuticals; Pharmacology; Proteins; Therapy EN Antibiotics Antineoplastics Biological Factors Cytokines Drugs and Therapies Health and Medicine Indolequinones Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Mitomycin Therapy Mitomycins Neoplasia Peptides Pharmaceuticals Pharmacology Proteins Therapy 1551 1551 1 08/14/23 20230814 NES 230814 2023 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on neoplasia. Antibiotics, Antineoplastics, Biological Factors, Cytokines, Drugs and Therapies, Health and Medicine, Indolequinones, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Mitomycin Therapy, Mitomycins, Neoplasia, Peptides, Pharmaceuticals, Pharmacology, Proteins, Therapy. [Extracted from the article]

According to news reporting originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Patients who have Lyme neuroborreliosis (LNB) might experience lingering symptoms that persist despite antibiotic drug therapy. Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Antibacterials, Antibiotics, Antimicrobials, Biological Factors, Borrelia Infections, Central Nervous System Bacterial Infections, Central Nervous System Diseases and Conditions, Central Nervous System Infections, Cytokines, Drugs and Therapies, Gram-Negative Bacteria, Health and Medicine, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Lyme Disease, Lyme Neuroborreliosis, Peptides, Proteins, Therapy, Tick-Borne Diseases and Conditions, Tufts University. [Extracted from the article]

For more information on this research see: In Vitro Evaluation of Apoptosis, Inflammation, Angiogenesis, and Neuroprotection Gene Expression In Retinal Pigmented Epithelial Cell Treated With Interferon Alpha-2b. Keywords: Shiraz; Iran; Angiogenesis; Apoptosis; Biological Factors; Biological Pigments; Cellular Physiology; Cytokines; Drugs and Therapies; Epithelial Cells; Genetics; Health and Medicine; Inflammation; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Peptides; Proteins; Retinal Pigments; Risk and Prevention EN Shiraz Iran Angiogenesis Apoptosis Biological Factors Biological Pigments Cellular Physiology Cytokines Drugs and Therapies Epithelial Cells Genetics Health and Medicine Inflammation Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Peptides Proteins Retinal Pigments Risk and Prevention 1179 1179 1 07/17/23 20230721 NES 230721 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Cellular Physiology - Apoptosis are discussed in a new report. [Extracted from the article]

45 patients received initial treatment with interferon alfa-2b (16 of whom crossed over to DA-EPOCH-R) and 18 received initial treatment with DA-EPOCH-R (eight of whom crossed over to interferon alfa-2b); four underwent surveillance only. [Extracted from the article]

Keywords for this news article include: Freiburg, Germany, Europe, Biological Factors, Cytokines, Health and Medicine, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Neoplasia, Peptides, Proteins, University Medical Center Freiburg. Keywords: Freiburg; Germany; Europe; Biological Factors; Cytokines; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Neoplasia; Peptides; Proteins EN Freiburg Germany Europe Biological Factors Cytokines Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Neoplasia Peptides Proteins 1685 1685 1 07/03/23 20230707 NES 230707 2023 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Fresh data on NeoplAsia are presented in a new report. Freiburg, Germany, Europe, Biological Factors, Cytokines, Health and Medicine, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Neoplasia, Peptides, Proteins. [Extracted from the article]

The content of interleukin-1 beta in children with recurrent episodes of acute obstructive bronchitis was significantly higher than in healthy children, after immunomodulatory therapy with recombinant interferon alpha-2 beta, interleukin-4 normalized to its level in healthy children." Keywords: Lvov; Ukraine; Europe; Biological Factors; Bronchial Diseases and Conditions; Bronchitis; Cytokines; Genetics; Health and Medicine; Immunology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukin-4; Interleukins; Lung Diseases and Conditions; Obstructive Lung Diseases and Conditions; Pediatrics; Peptides; Proteins; Pulmonology; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Risk and Prevention; Therapy EN Lvov Ukraine Europe Biological Factors Bronchial Diseases and Conditions Bronchitis Cytokines Genetics Health and Medicine Immunology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukin-4 Interleukins Lung Diseases and Conditions Obstructive Lung Diseases and Conditions Pediatrics Peptides Proteins Pulmonology Respiratory Tract Diseases and Conditions Respiratory Tract Infections Risk and Prevention Therapy 133 133 1 07/03/23 20230707 NES 230707 2023 JUL 8 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- Investigators publish new report on Lung Diseases and Conditions - Bronchitis. [Extracted from the article]

For more information on this research see: Interferon-alpha Regulates Abnormally Increased Expression of Rsad2 In Th17 and Tfh Cells In Systemic Lupus Erythematosus Patients. Keywords: Hunan; People's Republic of China; Asia; Autoimmune Diseases and Conditions; Biological Factors; Cytokines; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Lupus; Peptides; Proteins; Systemic Lupus Erythematosus EN Hunan People's Republic of China Asia Autoimmune Diseases and Conditions Biological Factors Cytokines Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Lupus Peptides Proteins Systemic Lupus Erythematosus 264 264 1 06/26/23 20230630 NES 230630 2023 JUN 30 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators publish new report on Autoimmune Diseases and Conditions - Lupus. [Extracted from the article]

Keywords: Dordrecht; Netherlands; Europe; Antineoplastics; Antivirals; BCR-ABL Tyrosine Kinase Inhibitors; Biological Factors; Cytokines; Drugs and Therapies; Health and Medicine; Imatinib Therapy; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Nilotinib; Nilotinib Therapy; Peginterferon Alfa-2b Therapy; Peptides; Pharmaceuticals; Protein Kinase Inhibitors; Proteins; Tyrosine Kinase Inhibitors EN Dordrecht Netherlands Europe Antineoplastics Antivirals BCR-ABL Tyrosine Kinase Inhibitors Biological Factors Cytokines Drugs and Therapies Health and Medicine Imatinib Therapy Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Nilotinib Nilotinib Therapy Peginterferon Alfa-2b Therapy Peptides Pharmaceuticals Protein Kinase Inhibitors Proteins Tyrosine Kinase Inhibitors 878 878 1 06/12/23 20230616 NES 230616 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Antivirals have been published. Keywords for this news article include: Dordrecht, Netherlands, Europe, Antineoplastics, Antivirals, BCR-ABL Tyrosine Kinase Inhibitors, Biological Factors, Cytokines, Drugs and Therapies, Health and Medicine, Imatinib Therapy, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Nilotinib, Nilotinib Therapy, Peginterferon Alfa-2b Therapy, Peptides, Pharmaceuticals, Protein Kinase Inhibitors, Proteins, Tyrosine Kinase Inhibitors, Albert Schweitzer Hospital. [Extracted from the article]

Keywords: Guangzhou; People's Republic of China; Asia; Antigens; Biological Factors; Chronic Hepatitis B Virus; Cytokines; DNA Viruses; Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hepadnaviridae; Hepatitis; Hepatitis B Virus; Hepatology; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Microbiological Processes; Orthohepadnavirus; Peptides; Proteins; Risk and Prevention; Therapy; Virology; Virus Physiological Phenomena; Virus Physiological Processes; Virus Replication EN Guangzhou People's Republic of China Asia Antigens Biological Factors Chronic Hepatitis B Virus Cytokines DNA Viruses Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hepadnaviridae Hepatitis Hepatitis B Virus Hepatology Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Microbiological Processes Orthohepadnavirus Peptides Proteins Risk and Prevention Therapy Virology Virus Physiological Phenomena Virus Physiological Processes Virus Replication 505 505 1 06/12/23 20230612 NES 230612 2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Current study results on Liver Diseases and Conditions - Chronic Hepatitis B Virus have been published. For more information on this research see: The Role of Alpk1 In Inhibiting Hepatitis B Virus Replication Facilitates the Identification of Alpk1 P660l Variant for Predicting Response To Pegylated Interferon Alpha Therapy. [Extracted from the article]

Keywords: Biological Factors; Chronic Hepatitis; Chronic Hepatitis B Virus; Cytokines; Digestive System Diseases and Conditions; Endocrine System Diseases and Conditions; Endocrinology; Gastroenterology; Health and Medicine; Hepatitis; Hyperthyroidism; Hypothyroidism; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Peptides; Proteins; Thyroid Diseases and Conditions EN Biological Factors Chronic Hepatitis Chronic Hepatitis B Virus Cytokines Digestive System Diseases and Conditions Endocrine System Diseases and Conditions Endocrinology Gastroenterology Health and Medicine Hepatitis Hyperthyroidism Hypothyroidism Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Peptides Proteins Thyroid Diseases and Conditions 357 357 1 06/12/23 20230612 NES 230612 2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- New research on chronic hepatitis B virus is the subject of a new report. Compared with patients with hypothyroidism/subclinical hypothyroidism, patients with hyperthyroidism/subclinical hyperthyroidism showed greater reduction and seroclearance of hepatitis B surface antigen (HBsAg) levels.". [Extracted from the article]

Keywords: Antiinfectives; Antiretrovirals; Antivirals; Biological Factors; Chronic Hepatitis; Chronic Hepatitis B Virus; Cytokines; DNA Viruses; Dicarboxylic Acids; Digestive System Diseases and Conditions; Drugs and Therapies; Fumarates; Gastroenterology; Health and Medicine; Hepadnaviridae; Hepadnaviridae Infections; Hepatitis; Hepatitis B Virus; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukins; Liver Diseases and Conditions; Nucleoside Reverse Transcriptase Inhibitors (NRTIs); Orthohepadnavirus; Peptides; Pharmaceuticals; Proteins; Risk and Prevention; Tenofovir Disoproxil Therapy; Tenofovir Therapy; Viral EN Antiinfectives Antiretrovirals Antivirals Biological Factors Chronic Hepatitis Chronic Hepatitis B Virus Cytokines DNA Viruses Dicarboxylic Acids Digestive System Diseases and Conditions Drugs and Therapies Fumarates Gastroenterology Health and Medicine Hepadnaviridae Hepadnaviridae Infections Hepatitis Hepatitis B Virus Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukins Liver Diseases and Conditions Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Orthohepadnavirus Peptides Pharmaceuticals Proteins Risk and Prevention Tenofovir Disoproxil Therapy Tenofovir Therapy Viral 653 653 1 06/05/23 20230605 NES 230605 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Fresh data on chronic hepatitis B virus are presented in a new report. For more information on this research see: The expression of interleukin-1b in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. [Extracted from the article]

Keywords: Biological Factors; Cancer; Cytokines; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Oncology; Peptides; Prostate Cancer; Prostatic Neoplasms; Proteins EN Biological Factors Cancer Cytokines Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Oncology Peptides Prostate Cancer Prostatic Neoplasms Proteins 983 983 1 05/22/23 20230526 NES 230526 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on prostate cancer have been published. CHRM4 overexpression may drive neuroendocrine differentiation of prostate cancer cells and is associated with immunosuppressive cytokine responses in the tumor microenvironment (TME) of prostate cancer. [Extracted from the article]

Keywords: Mexico City; Mexico; North and Central America; Autoimmune Diseases and Conditions; Biological Factors; Chemokine Receptors; Chemokines; Chemotactic Factors; Cytokine Receptors; Cytokines; Dry Eye Syndrome; G-Protein-Coupled Receptors; Genetics; Health and Medicine; Immunology; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Joint Diseases and Conditions; Lacrimal Apparatus Diseases and Conditions; Membrane Proteins; Mouth Diseases and Conditions; Musculoskeletal Diseases and Conditions; Peptides; Proteins; Rheumatic Diseases and Conditions; Salivary Gland Diseases and Conditions; Sjogren's Syndrome; Skin and Connective Tissue Diseases and Conditions; Stomatognathic Diseases and Conditions; Xerostomia EN Mexico City Mexico North and Central America Autoimmune Diseases and Conditions Biological Factors Chemokine Receptors Chemokines Chemotactic Factors Cytokine Receptors Cytokines Dry Eye Syndrome G-Protein-Coupled Receptors Genetics Health and Medicine Immunology Inflammation Mediators Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Joint Diseases and Conditions Lacrimal Apparatus Diseases and Conditions Membrane Proteins Mouth Diseases and Conditions Musculoskeletal Diseases and Conditions Peptides Proteins Rheumatic Diseases and Conditions Salivary Gland Diseases and Conditions Sjogren's Syndrome Skin and Connective Tissue Diseases and Conditions Stomatognathic Diseases and Conditions Xerostomia 1381 1381 1 05/15/23 20230519 NES 230519 2023 MAY 19 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators discuss new findings in Autoimmune Diseases and Conditions - Sjogren's Syndrome. [Extracted from the article]

Keywords: Biological Factors; Blood Cells; CD Antigens; CD8 Antigens; Cytokines; Health and Medicine; Hemic and Immune Systems; Immunology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Lymphocytes; Mononuclear Leukocytes; Peptides; Proteins; T-Lymphocyte Antigens EN Biological Factors Blood Cells CD Antigens CD8 Antigens Cytokines Health and Medicine Hemic and Immune Systems Immunology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Lymphocytes Mononuclear Leukocytes Peptides Proteins T-Lymphocyte Antigens 21 21 1 05/15/23 20230515 NES 230515 2023 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Research findings on interferon type I are discussed in a new report. Supernatants collected from CD8+ T cell cultures were screened for their ability to suppress HIV-1 replication in vitro and their interferon-alpha concentrations were measured by ELISA. [Extracted from the article]

Keywords: Madrid; Spain; Europe; Anterior Uveitis; Biological Factors; Cytokines; Eye Diseases and Conditions; Health and Medicine; Inflammation; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Neoplasia; Ophthalmology; Peptides; Proteins; Uveal Diseases and Conditions; Uveitis EN Madrid Spain Europe Anterior Uveitis Biological Factors Cytokines Eye Diseases and Conditions Health and Medicine Inflammation Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Neoplasia Ophthalmology Peptides Proteins Uveal Diseases and Conditions Uveitis 5608 5608 1 05/08/23 20230512 NES 230512 2023 MAY 12 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Eye Diseases and Conditions - Anterior Uveitis have been published. According to the news editors, the research concluded: "It may be reasonable to use IFN-a2b cautiously in patients with a known history of uveitis or uveitis predisposition.". [Extracted from the article]

Keywords: Biological Factors; Bronchial Diseases and Conditions; Bronchitis; Cytokines; Genetics; Health and Medicine; Immunology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukin-4; Interleukins; Lung Diseases and Conditions; Obstructive Lung Diseases and Conditions; Pediatrics; Peptides; Proteins; Pulmonology; Respiratory Tract Diseases and Conditions; Respiratory Tract Infections; Risk and Prevention; Therapy EN Biological Factors Bronchial Diseases and Conditions Bronchitis Cytokines Genetics Health and Medicine Immunology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukin-4 Interleukins Lung Diseases and Conditions Obstructive Lung Diseases and Conditions Pediatrics Peptides Proteins Pulmonology Respiratory Tract Diseases and Conditions Respiratory Tract Infections Risk and Prevention Therapy 923 923 1 05/08/23 20230512 NES 230512 2023 MAY 8 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Research findings on bronchitis are discussed in a new report. It was found that children with recurrent episodes of acute obstructive bronchitis have an imbalance of cytokines, the effectiveness of recombinant human interferon alpha-2b therapy, which normalised the levels of the studied cytokines in the serum.". [Extracted from the article]

Wroclaw, Poland, Europe, Amino Acids, Aromatic Amino Acids, Biological Factors, Cytokines, Digestive System Diseases and Conditions, Essential Amino Acids, Gastroenterology, Health and Medicine, Hepatitis, Infectious Diseases and Conditions, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Liver Diseases and Conditions, Peptides, Proteins, Tryptophan Keywords: Wroclaw; Poland; Europe; Amino Acids; Aromatic Amino Acids; Biological Factors; Cytokines; Digestive System Diseases and Conditions; Essential Amino Acids; Gastroenterology; Health and Medicine; Hepatitis; Infectious Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Liver Diseases and Conditions; Peptides; Proteins; Tryptophan EN Wroclaw Poland Europe Amino Acids Aromatic Amino Acids Biological Factors Cytokines Digestive System Diseases and Conditions Essential Amino Acids Gastroenterology Health and Medicine Hepatitis Infectious Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Liver Diseases and Conditions Peptides Proteins Tryptophan 573 573 1 05/08/23 20230508 NES 230508 2023 MAY 8 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Data detailed on Liver Diseases and Conditions - Hepatitis have been presented. Keywords for this news article include: Wroclaw, Poland, Europe, Amino Acids, Aromatic Amino Acids, Biological Factors, Cytokines, Digestive System Diseases and Conditions, Essential Amino Acids, Gastroenterology, Health and Medicine, Hepatitis, Infectious Diseases and Conditions, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Liver Diseases and Conditions, Peptides, Proteins, Tryptophan, Wroclaw Medical University. [Extracted from the article]

For more information on this research see: Interferon-alpha 1 expression indicates the disease activity and response of patients with ankylosing spondylitis to anti-TNF-a treatment. Keywords: Ankylosing Spondylitis; Biological Factors; Bone Diseases and Conditions; C-Reactive Protein; Cytokines; Genetics; Health and Medicine; Infectious Bone Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Membrane Proteins; Musculoskeletal Diseases and Conditions; Peptides; Protein Expression; Proteins; Proteomics; Rheumatology; Spinal Diseases and Conditions; Spondylitis; Tumor Necrosis Factors EN Ankylosing Spondylitis Biological Factors Bone Diseases and Conditions C-Reactive Protein Cytokines Genetics Health and Medicine Infectious Bone Diseases and Conditions Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Membrane Proteins Musculoskeletal Diseases and Conditions Peptides Protein Expression Proteins Proteomics Rheumatology Spinal Diseases and Conditions Spondylitis Tumor Necrosis Factors 1583 1583 1 04/24/23 20230428 NES 230428 2023 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Data detailed on ankylosing spondylitis have been presented. [Extracted from the article]

Keywords: Jiangsu; People's Republic of China; Asia; Biological Factors; Cytokines; Genetics; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Peptides; Proteins EN Jiangsu People's Republic of China Asia Biological Factors Cytokines Genetics Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Peptides Proteins 268 268 1 04/17/23 20230421 NES 230421 2023 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New research on Intercellular Signaling Peptides and Proteins - Interferon Type I is the subject of a report. Ten hub genes included interferon alpha-inducible protein 27, human leucocyte antigen-G, interferon-induced protein with tetratricopeptide repeats 2, 2'-5'-oligoadenylate synthetase 2, interferon alpha-inducible protein 6, interferon alpha-inducible protein 44-like, interferon-induced protein with tetratricopeptide repeats 3, interferon regulatory factor 5, myxovirus resistant 1, and interferon-induced protein with tetratricopeptide repeats 1. [Extracted from the article]

The crossover treatments were also effective, with the disease disappearing in 4 of 8 patients (50%) treated with interferon alfa-2b after chemotherapy and 7 of 15 patients (47%) treated with chemotherapy after interferon alfa-2b. Patients with low-grade disease that worsened after immunotherapy were given chemotherapy, whereas patients with high-grade disease that came back after chemotherapy were given interferon alfa-2b. Median overall survival was 20.6 years for patients treated initially with interferon alfa-2b and 19.8 years for patients who crossed over to receive interferon alfa-2b. [Extracted from the article]

According to the news reporters, the research concluded: "Exercise training influenced 3xTg mice cortex through interferon alpha beta signaling upregulation and extracellular matrix organization downregulation based on transcriptomics analysis." Keywords: Alzheimer Disease; Biological Factors; Brain Diseases and Conditions; Brain Research; Central Nervous System; Central Nervous System Diseases and Conditions; Cerebral Cortex; Cerebrum; Cytokines; Dementia; Genetics; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Neurodegenerative Diseases and Conditions; Peptides; Prosencephalon; Proteins; Tauopathies EN Alzheimer Disease Biological Factors Brain Diseases and Conditions Brain Research Central Nervous System Central Nervous System Diseases and Conditions Cerebral Cortex Cerebrum Cytokines Dementia Genetics Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Neurodegenerative Diseases and Conditions Peptides Prosencephalon Proteins Tauopathies 1940 1940 1 04/10/23 20230414 NES 230414 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Data detailed on Alzheimer disease have been presented. [Extracted from the article]

Keywords for this news article include: University Hospital Arnau de Vilanova, Lleida, Spain, Europe, Cytokines, Melanosis, Cryotherapy, Therapeutics, Interferon-alpha, Hyperpigmentation, Interferon Type I, Biological Factors, Health and Medicine, Surgical Procedures, Pigmentation Disorders, Skin Diseases and Conditions, Intercellular Signaling Peptides and Proteins, Skin and Connective Tissue Diseases and Conditions. Keywords: Biological Factors; Cryotherapy; Cytokines; Health and Medicine; Hyperpigmentation; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Melanosis; Peptides; Pigmentation Disorders; Proteins; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Surgical Procedures; Therapeutics; Therapy EN Biological Factors Cryotherapy Cytokines Health and Medicine Hyperpigmentation Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Melanosis Peptides Pigmentation Disorders Proteins Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Surgical Procedures Therapeutics Therapy 1862 1862 1 04/10/23 20230410 NES 230410 2023 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Data detailed on melanosis have been presented. Biological Factors, Cryotherapy, Cytokines, Health and Medicine, Hyperpigmentation, Intercellular Signaling Peptides and Proteins, Interferon-alpha, Interferons, Melanosis, Interferon Type I, Peptides, Pigmentation Disorders, Proteins, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions, Surgical Procedures, Therapeutics, Therapy. [Extracted from the article]

For more information on this research see: Preemptive Interferon-alpha Therapy Could Prevent Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation: a Real-world Analysis. Keywords: Beijing; People's Republic of China; Asia; Acute Myeloid Leukemia; Biological Factors; Biomedicine; Bone Marrow Cells; Cancer; Cell Transplantation; Cell Transplants; Cytokines; Health and Medicine; Hematology; Hematopoietic; Hematopoietic Stem Cells; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Leukemia; Myeloid Leukemia; Oncology; Peptides; Proteins; Risk and Prevention; Stem Cell Research; Surgery; Transplant Medicine EN Beijing People's Republic of China Asia Acute Myeloid Leukemia Biological Factors Biomedicine Bone Marrow Cells Cancer Cell Transplantation Cell Transplants Cytokines Health and Medicine Hematology Hematopoietic Hematopoietic Stem Cells Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Leukemia Myeloid Leukemia Oncology Peptides Proteins Risk and Prevention Stem Cell Research Surgery Transplant Medicine 611 611 1 03/27/23 20230331 NES 230331 2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Current study results on Oncology - Acute Myeloid Leukemia have been published. [Extracted from the article]

Keywords: Olomouc; Czech Republic; Europe; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Biological Factors; Cancer; Chemotherapy; Chronic Myeloid Leukemia; Cytokines; Dasatinib Therapy; Drugs and Therapies; Health and Medicine; Hematology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Leukemia; Myeloid Leukemia; Oncology; Peptides; Pharmaceuticals; Proteins; Sprycel Therapy; Tyrosine Kinase Inhibitors EN Olomouc Czech Republic Europe Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Biological Factors Cancer Chemotherapy Chronic Myeloid Leukemia Cytokines Dasatinib Therapy Drugs and Therapies Health and Medicine Hematology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Leukemia Myeloid Leukemia Oncology Peptides Pharmaceuticals Proteins Sprycel Therapy Tyrosine Kinase Inhibitors 2389 2389 1 03/27/23 20230330 NES 230330 2023 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Oncology - Chronic Myeloid Leukemia have been published. Keywords for this news article include: Olomouc, Czech Republic, Europe, Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Biological Factors, Cancer, Chemotherapy, Chronic Myeloid Leukemia, Cytokines, Dasatinib Therapy, Drugs and Therapies, Health and Medicine, Hematology, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Leukemia, Myeloid Leukemia, Oncology, Peptides, Pharmaceuticals, Proteins, Sprycel Therapy, Tyrosine Kinase Inhibitors, Palacky University. [Extracted from the article]

MethodsA total of 162 CHB patients who were admitted to several hospitals in Qingdao, China, from 2018 to 2021 were enrolled as subjects, and all patients received pegylated interferon a-2b for at least 48 weeks after NUC therapy for one year or longer." Keywords: Bile Pigments; Bilirubin; Biological Factors; Chronic Hepatitis B Virus; Cytokines; Health and Medicine; Intercellular Signaling Peptides and Proteins; Interferon Alfa-2b; Interferon-alpha; Interferons; Liver Diseases and Conditions; Peptides; Proteins; Recombinant Interferon Type I; Therapy EN Bile Pigments Bilirubin Biological Factors Chronic Hepatitis B Virus Cytokines Health and Medicine Intercellular Signaling Peptides and Proteins Interferon Alfa-2b Interferon-alpha Interferons Liver Diseases and Conditions Peptides Proteins Recombinant Interferon Type I Therapy 116 116 1 03/27/23 20230328 NES 230328 2023 MAR 27 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- Fresh data on chronic hepatitis B virus are presented in a new report. For more information on this research see: Predictive factors for functional cure after sequential therapy with nucleos(t)ide analogues and pegylated interferon alfa-2b in treatment of chronic hepatitis B. Linchuang Gandanbing Zazhi, 2023,39(2):299-306. [Extracted from the article]

Other stable mood disorders on stable therapy for 6 months or not requiring therapy may be allowed after consultation with the principal investigator.) Cardiac risk factors including: Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent. Note: For cohort 1 and cohort 2: Patient with accessible tumor will be offered optional pre-treatment and post-treatment biopsies. [Extracted from the article]

In some embodiments, the HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with chronic HBV infection and/or HDV infection. "Certain Hepatitis B Virus-specific RNA interference (RNAi) agents have been previously shown to inhibit expression of HBV gene expression. An antisense strand of an HBV RNAi agent comprises a nucleotide sequence having at least about 85% complementary over a core stretch of at least 16 consecutive nucleotides to a sequence in an HBV mRNA and the corresponding sense strand. Further, there exists a need for combinations of novel HBV-specific RNAi agents for the treatment of HBV infection and prevention of diseases associated with HBV. [Extracted from the article]

This study observed the efficacy and safety of this regimen in the treatment of numbers of AML patients in various disease states." Keywords: Zhengzhou; People's Republic of China; Asia; Acute Myeloid Leukemia; Antiinfectives; Antineoplastics; Biological Factors; Cancer; Carboxylic Acids; Cytokines; Drugs and Therapies; Genetics; Health and Medicine; Hematology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukin-2; Interleukins; Leprostatics; Leukemia; Lymphokines; Myeloid Leukemia; Oncology; Organic Chemicals; Peptides; Pharmaceuticals; Phthalimides; Proteins; Thalidomide; Thalidomide Therapy EN Zhengzhou People's Republic of China Asia Acute Myeloid Leukemia Antiinfectives Antineoplastics Biological Factors Cancer Carboxylic Acids Cytokines Drugs and Therapies Genetics Health and Medicine Hematology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukin-2 Interleukins Leprostatics Leukemia Lymphokines Myeloid Leukemia Oncology Organic Chemicals Peptides Pharmaceuticals Phthalimides Proteins Thalidomide Thalidomide Therapy 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Acute Myeloid Leukemia. Sixty patients with primary AML who were unable to receive chemotherapy, or with relapsed/refractory AML, showed a total response rate of 28.3% (17/60) after receiving the ITI regimen. [Extracted from the article]